Our Leadership

Novocure is managed by a team of senior leaders with extensive experience across the oncology, biotechnology and medical device industries.

Bill Doyle

Chairman of the Board

Bill doyle

Bill Doyle is Managing Partner of venture capital investor WFD Ventures LLC and a member of the Investment Team of Pershing Square Capital, L.P.  Previously, Bill was an executive of Johnson & Johnson where he served as a member of Johnson & Johnson’s Consumer Pharmaceuticals and Medical Devices Group Operating Committee and Vice President, Licensing and Acquisitions. At J&J, Bill was also Chairman of the Medical Devices Research and Development Council, Worldwide President of Biosense-Webster and a member of the boards of directors of Cordis and Johnson & Johnson Development Corporation. Earlier in his career Bill was a consultant with McKinsey & Company. Bill holds an S.B. in materials science and engineering from the Massachusetts Institute of Technology and an MBA from Harvard Business School.

Asaf Danziger

Chief Executive Officer

Asaf danziger

Asaf Danziger has served as Chief Executive Officer of Novocure since 2002 and is also a member of the board of directors.  Asaf has led the company and the development of TTFields therapy from preclinical testing through regulatory approvals in Europe and the United States, and to commercial sales.  From 1998 to 2002, Mr. Danziger was CEO of Cybro Medical, a subsidiary of Imagyn Medical Technologies.  Mr. Danziger holds a B.Sc. in material engineering from Ben Gurion University of the Negev, Israel. 

Mike Ambrogi

Chief Operating Officer

Mike Ambrogi joined Novocure in 2006 and serves as Chief Operating Officer. Mike has overall responsibility for Novocure’s ongoing clinical, manufacturing, and service activities worldwide. Mike was previously the General Manager of Deka Research and Development, inventor Dean Kamen’s R&D firm. Mike led Deka’s teams on breakthrough products including the Baxter HomeChoice peritoneal dialysis machine, the Davol Hydroflex surgical irrigation device, the Cordis Crowne Stent, and the J&J IBOT 3000 mobility system. Earlier in his career, Mike was a consultant with McKinsey & Company. Mike holds a S.B. in mechanical engineering from the Massachusetts Institute of Technology (MIT).

Wilco Groenhuysen

Chief Financial Officer

Yoram palti

Wilco Groenhuysen joined Novocure in January 2012 as Chief Financial Officer. Wilco was previously executive vice president and CFO of Cephalon, Inc. where he had responsibility for worldwide finance, commercial operations and risk management. Prior to joining Cephalon in 2007 he spent 20 years with Philips Electronics in various assignments in Europe, Asia and the United States, latest of which started in 2002 when he was promoted to CFO and senior vice president of Philips Electronics North America Corporation.

Eilon Kirson, M.D., Ph.D.

Chief Science Officer and Head of Research and Development

Dr. Kirson joined Novocure in 2002 and served as Chief Medical Officer until 2012 when he was promoted to Chief Science Officer and Head of Research and Development. Dr. Kirson has global responsibility for Novocure’s preclinical and clinical and product development programs, as well as the company’s regulatory strategy. In his tenure at Novocure, Dr. Kirson has led the development of TTFields therapy from pre-clinical testing to large, multi-center phase III studies and through multiple regulatory approvals. Dr. Kirson previously served as Head of Electrophysiology at Carmel Biosensensors. Dr. Kirson received his B.Med.Sc., M.D. and Ph.D. in Biophysics from the Hebrew University and underwent his residency in neurology at Sheba Medical Center, Tel Ha-Shomer Hospital, Israel.

Todd Longsworth

General Counsel

Yoram palti

Todd Longsworth joined Novocure in April 2012 and serves as General Counsel. Todd was previously chief M&A, securities and corporate governance counsel for Cephalon, Inc. Prior to joining Cephalon, he was an associate at WilmerHale LLP in Boston. Todd earned his B.A. from Duke University and his J.D. from the University of Pennsylvania.

Peter Melnyk

Chief Commercial Officer

Yoram palti

Peter Melnyk joined Novocure in 2011 and serves as Chief Commercial Officer. Peter has overall responsibility for directing the company’s global marketing and sales efforts and will lead the worldwide commercial launches for NovoTTF Therapy. Mr. Melnyk was previously Senior Vice President for Sales and Marketing at OSI Pharmaceuticals where he led the global commercialization efforts for Tarceva. Prior to OSI, Mr. Melnyk was executive director of oncology at Pfizer and Pharmacia and a director of oncology at Bristol-Myers Squibb. Mr. Melnyk also serves on the Cancer Prevention and Early Detection Advisory Workgroup of C-Change. Peter holds a BSc and MSc from McGill University.

Yoram Palti

Chief Technology Officer

Yoram palti

Professor Palti is a professor emeritus of physiology & biophysics at the Technion – Israel Institute of Technology, the inventor of TTF therapy and the company's founder. Professor Palti was also previously the head of the Rappaport Institute for Research in the Medical Sciences, the research arm of the Technion Medical School, for 12 years. Prior to his appointments at the Technion, he was an associate professor of physiology at the University of Maryland School of Medicine. He also founded and managed Carmel Biosensor Ltd. and CellSense Ltd. Professor Palti is the author of more than 40 patents and 70 scientific papers.

Delivered by Investis (opens in a new window)